Alentis Therapeutics
Presence
Acquisition, funding and merger involving Alentis Therapeutics.
- Alentis Therapeutics has just announced a $105 Million fundraising (posted on April 14 2023).
Executives
View the org chart displaying its 15 main executives
Most searched biographies at Alentis Therapeutics
- Roberto Iacone, Chief Executive Officer and Director
- Rafaèle Tordjman, Member of the Board
- William Pao, Independent Board Member
Popular executive movements at Alentis Therapeutics
- William Pao has joined the company as Independent Board Member (posted on January 8 2024).
- Izwan Velji has joined the company as Chief Business Officer (posted on December 7 2023).
Create your alert
to follow the executive moves at Alentis Therapeutics.
Biotechnology
Alentis Therapeutics has 2,275 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Bruker has announced the acquisition of NanoString Technologies (posted on April 18 2024).
- Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences (posted on April 16 2024).
- Nurix Therapeutics has just announced a $175 Million fundraising (posted on April 13 2024).
Popular contacts in Biotechnology
News
Press releases by Alentis Therapeutics
Social media about Alentis Therapeutics
- Alentis Therapeutics on Wikipedia, Google News & Yahoo Finance
- Alentis Therapeutics on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Roberto Iacone 
Call Alentis Therapeutics at +41 61...
